BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)

被引：0

作者：

Buti, Maria ^{[1
,2
]}

Gane, Edward J. ^{[3
]}

Agarwal, Kosh ^{[4
]}

Wong, Grace Lai-Hung C. ^{[5
]}

Lim, Young-Suk ^{[6
]}

Chen, Chi-Yi ^{[7
]}

Lim, Seng Gee ^{[8
]}

Yatsuhashi, Hiroshi ^{[9
]}

Fung, Scott K. ^{[10
]}

Abramov, Frida ^{[11
]}

Wang, Hongyuan ^{[11
]}

Yee, Leland J. ^{[11
]}

Flaherty, John F. ^{[11
]}

Pan, Calvin Q. ^{[12
]}

Marcellin, Patrick ^{[13
]}

机构：

[1] Hosp Univ Vall Dhebron, Barcelona, Spain

[2] Ciberehd Inst Carlos III, Madrid, Spain

[3] Univ Auckland, Auckland, New Zealand

[4] Kings Coll Hosp London, Inst Liver Studies, London, England

[5] Chinese Univ Hong Kong, MDAC, Hong Kong, Peoples R China

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[7] Chiayi Christian Hosp, Chiayi, Taiwan

[8] Natl Univ Hlth Syst, Singapore, Singapore

[9] Natl Hosp Org Nagasaki Med Ctr, Clin Res Ctr, Nagasaki, Japan

[10] Univ Toronto, Dept Med, Toronto, ON, Canada

[11] Gilead Sci Inc, Foster City, CA 94404 USA

[12] NYU, NYU Langone Hlth, Grossman Sch Med, New York, NY USA

[13] Univ Paris, Hop Beaujon, AP HP, Paris, France

来源：

HEPATOLOGY | 2023年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1405C

引用

页码：S507 / S509

页数：3

共 50 条

[41] Two Years Safety and Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Patients with HBV-Induced Cirrhosis
Buti, Maria
Hadziyannis, Stephanos J.
Mathurin, Philippe
Urbanek, Petr
Sherman, Morris
Strasser, Simone I.
Wang, Chia C.
Petersen, Joerg
Heathcote, Jenny
Marcellin, Patrick
Sorbel, Jeff
Mondou, Elsa
Anderson, Jane
Rousseau, Franck
GASTROENTEROLOGY, 2009, 136 (05) : A865 - A866
[42] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay Walter
Agarwal, Kosh
Brunetto, Maurizia R.
Janssen, Harry L. A.
Caruntu, Florin
Stepanova, Tatjana
Tsang, Owen
Yatsuhashi, Hiroshi
Tak, Won Young
Chen, Chi-Yi
Celen, Mustafa
Suri, Vithika
Flaherty, John F.
Lin, Lanjia
Cathcart, Andrea
Gaggar, Anuj
Pan, Calvin Q.
Shalimar
Buti, Maria
HEPATOLOGY, 2018, 68 : 227A - 228A
[43] Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hong, Hyeyeon
Choi, Won-Mook
Lee, Danbi
Shim, Ju Hyun
Kim, Kang Mo
Lim, Young-Suk
Lee, Han Chu
Choi, Jonggi
CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (01) : 49 - 63
[44] Reduced Changes In Bone Mineral Density In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared With Tenofovir disoproxil fumarate
Seto, Wai-Kay
Asahina, Yasuhiro
Peng, Cheng-Yuan
Stanciu, Carol
Abdurakhmanov, Djamal
Flaherty, John F.
Kim, Kyungpil
Gaggar, Anuj
Subramanian, Mani
Tabak, Fehmi
Nguyen, Tuan T.
Chan, Henry Lik-Yuen
HEPATOLOGY, 2016, 64 : 35A - 35A
[45] VIROLOGIC, BIOCHEMICAL, AND RENAL OUTCOMES OF TREATMENT-NAIVE PATIENTS WITH SEQUENTIAL THERAPY FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN ROUTINE PRACTICE
Toyoda, Hidenori
Trinh, Huy N.
Leong, Jennifer
Atsukawa, Masanori
Watanabe, Tsunamasa
Chuma, Makoto
Liu, Joanne
Yokohama, Keisuke
Dang, Hansen
Maeda, Mayumi
Le, Richard
Thin, Khin Naing
Tran, Sally
Chien, Nicholas
Takaguchi, Koichi
Fukunishi, Shinya
Yasuda, Satoshi
Cheung, Ramsey
Nguyen, Mindie H.
HEPATOLOGY, 2020, 72 : 498A - 499A
[46] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-NEGATIVE, CHRONIC HEPATITIS B PATIENTS: A GLOBAL PHASE 3 STUDY
Brunetto, Maurizia Rossana
Lim, Young-Suk
Gane, Edward
Seto, Wai-Kay
Osipenko, Marina
Ahn, Sang Hoon
Janssen, Harry L.
Shukla, Akash
Chuang, Wan-Long
Trinh, Huy N.
Celen, Mustafa
Flaherty, John F.
Chan, Alain
Lau, Audrey
Gaggar, Anuj
Suri, Vithika
Subramanian, Mani
Pan, Calvin Q.
Izumi, Namiki
Marcellin, Patrick
Chan, Henry L.
Buti, Maria
GASTROENTEROLOGY, 2017, 152 (05) : S1086 - S1086
[47] Twenty Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients
Agarwal, Kosh
Fung, Scott K.
Nguyen, Tuan T.
Cheng, Wendy
Sicard, Eric
Ryder, Stephen D.
Flaherty, John F.
Lawson, Eileen
Zhao, Sally
Subramanian, Mani
McHutchison, John G.
Gane, Edward J.
Foster, Graham R.
HEPATOLOGY, 2013, 58 : 675A - 675A
[48] Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
Wang, Fa-Da
Zhou, Jing
Li, Lan-Qing
Li, Yu-Jing
Wang, Meng -Lan
Tao, Ya-Chao
Zhang, Dong-Mei
Wang, Yong-Hong
Chen, En-Qiang
ANNALS OF HEPATOLOGY, 2023, 28 (05)
[49] CORRELATIONS BETWEEN NON-INVASIVE BIOMARKERS AND FIBROSIS SCORES IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) AND TENOFOVIR ALAFENAMIDE (TAF) IN PHASE 3 CLINICAL TRIALS
Ferret, Maria Asuncion Buti
Gane, Edward J.
Marcellin, Patrick
Jacobson, Ira M.
Janssen, Harry L. A.
Agarwal, Kosh
Fung, Scott K.
Chuang, Wan-Long
Pan, Calvin
Flaherty, John F.
Wang, Hongyuan
Tan, Susanna
Suri, Vithika
Gaggar, Anuj
Limw, Young-Suk
Chan, Henry Lik Yuen
HEPATOLOGY, 2020, 72 : 479A - 480A
[50] IMPACT OF LONG- TERM TREATMENT WITH CONTINUOUS TENOFOVIR ALAFENAMIDE ( TAF) OR AFTER SWITCH FROM TENOFOVIR DISOPROXIL FUMARATE ( TDF) ON HEPATOCELLULAR CARCINOMA ( HCC) INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS B ( CHB)
Lim, Young-Suk
Wong, Grace Lai-Hung C.
Ahn, Sang Hoon
Seto, Wai-Kay
Agarwal, Kosh
Janssen, Harry L. A.
Pan, Calvin Q.
Chuang, Wan Long
Fung, Scott K.
Shalimar
Brunetto, Maurizia R.
Hui, Aric Josun
Chang, Ting-Tsung
Lim, Seng Gee
Abramov, Frida
Flaherty, John F.
Wang, Hongyuan
Yee, Leland J.
Kao, Jia-Horng
Marcellin, Patrick
Gane, Edward J.
Buti, Maria
HEPATOLOGY, 2023, 78 : S523 - S526

← 1 2 3 4 5 →